Application
Givinostat hydrochloride hydrate has been used as a histone deacetylase inhibitor to test its effect on the human immunodeficiency virus reactivation in CD4+ T-cell model.
Biochem/physiol Actions
Givinostat (ITF2357) is a hydroxamate HDAC inhibitor that inhibits class I and class II enzymes.
Givinostat (ITF2357) is a hydroxamate HDAC inhibitor that inhibits class I and class II enzymes. Givinostat posseses a very promising activity profile in multiple myeloma and acute myelogenous leukemia in vitro and in vivo. Givinostat also has anti-inflammatory activity and inhibits the secretion of the tumor necrosis factor-alpha (TNF-α), IL-1, and IL-6. Givinostat has been in multiple Phase 2 studies for both inflammatory diseases (Duchenne Muscular Dystrophy , Juvenile arthritis, Polycythemia Vera) and blood cancers (myelomas and lymphomas).
Givinostat is known to mediate the reduction of the human immunodeficiency virus release in macrophages.
| Quality Level | 100 |
| assay | ≥95% (HPLC) |
| form | powder |
| storage condition | desiccated |
| color | white to beige |
| solubility | DMSO: 20 mg/mL, clear |
| storage temp. | −20°C |
| SMILES string | [H]Cl.[H]O[H].CCN(CC)CC1=CC=C(C=C(COC(NC2=CC=C(C(NO)=O)C=C2)=O)C=C3)C3=C1 |
| InChI | 1S/C24H27N3O4.ClH.H2O/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30;;/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28);1H;1H2 |
| InChI key | FKGKZBBDJSKCIS-UHFFFAOYSA-N |
